Teladoc Health Stock Forecast, Price & News

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last twelve months. There are currently 11 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Teladoc Health stock.
View analyst ratings for Teladoc Health or view top-rated stocks.

Wall Street analysts have given Teladoc Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Teladoc Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Teladoc Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Teladoc Health.

Teladoc Health, Inc. (NYSE:TDOC) posted its quarterly earnings data on Wednesday, April, 28th. The health services provider reported $0.13 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.70. The health services provider earned $453.68 million during the quarter, compared to analyst estimates of $452.12 million. Teladoc Health had a negative net margin of 47.93% and a negative trailing twelve-month return on equity of 0.60%. The business's quarterly revenue was up 150.9% on a year-over-year basis. During the same period last year, the business earned ($0.40) earnings per share.
View Teladoc Health's earnings history.

Teladoc Health's stock was trading at $137.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TDOC shares have increased by 12.7% and is now trading at $154.82.
View which stocks have been most impacted by COVID-19.

Teladoc Health updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $1.97 billion-$2.02 billion, compared to the consensus revenue estimate of $1.99 billion.

29 Wall Street analysts have issued 1-year price objectives for Teladoc Health's stock. Their forecasts range from $162.00 to $300.00. On average, they expect Teladoc Health's share price to reach $241.45 in the next year. This suggests a possible upside of 56.0% from the stock's current price.
View analysts' price targets for Teladoc Health or view top-rated stocks among Wall Street analysts.

106 employees have rated Teladoc Health CEO Jason Gorevic on Glassdoor.com. Jason Gorevic has an approval rating of 95% among Teladoc Health's employees. This puts Jason Gorevic in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Teladoc Health include 1Life Healthcare (ONEM), Hims & Hers Health (HIMS), Cano Health (CANO), Jaws Acquisition (JWS), LifeMD (LFMD), Concord Medical Services (CCM) and WellQuest Medical & Wellness (WEQL).
View all of TDOC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), Shopify (SHOP), DocuSign (DOCU), salesforce.com (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

(TDOC) raised $112 million in an initial public offering on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (9.33%), BlackRock Inc. (5.71%), Baillie Gifford & Co. (5.15%), General Catalyst Group Management LLC (4.34%), Sumitomo Mitsui Trust Holdings Inc. (3.10%) and Nikko Asset Management Americas Inc. (2.88%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen, Stephany Verstraete, William H Frist and Yulun Wang.
View institutional ownership trends for Teladoc Health.

TDOC stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Victory Capital Management Inc., Aequim Alternative Investments LP, BlackRock Inc., General Catalyst Group Management LLC, Massachusetts Financial Services Co. MA, Waddell & Reed Financial Inc., and Putnam Investments LLC. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Glen Tullman, Hemant Taneja, Jason N Gorevic, Lewis Levy, Mala Murthy, Stephany Verstraete, William H Frist, and Yulun Wang.
View insider buying and selling activity for Teladoc Health or view top insider-selling stocks.

TDOC stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Baillie Gifford & Co., Himension Fund, Discovery Value Fund, Geode Capital Management LLC, and Cigna Investments Inc. New.
View insider buying and selling activity for Teladoc Health or or view top insider-buying stocks.

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TDOC stock can currently be purchased for approximately $154.82.

Teladoc Health has a market capitalization of $23.92 billion and generates $1.09 billion in revenue each year. The health services provider earns $-485,140,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

Teladoc Health employs 4,400 workers across the globe.

The following companies are subsidiares of Teladoc Health: AM Healthcare Management Consulting Sdn. Bhd., AMHMS - Health Care Management Services S.A., Advance Holdco Limited, Advance Medical, Advance Medical - Serviços de Consultoria e Gestão de Dados Ltda, Advance Medical Health Care Management Services Chile S.A., Advance Medical Hungary Tanácsadó és Szolgáltató Korlátolt Felelösségü Társaság, Advance Medical Inc., AmeriDoc, Best Doctors, Best Doctors Australasia Pty Limited, Best Doctors Holdings Inc., Best Doctors Inc., Best Doctors International Insurance S.a.r.l., Best Doctors Portugal Ltd., BetterHelp, CogCubed, Compile Inc., Consult A Doctor, HY Holdings Inc., Healthiest You, Institute of Patient Safety and Quality in Virtual Care LLC, Intouch Health, Livongo, MedecinDirect, Médecin Direct, Rise Health Inc., Stat Doctors, Stat Health LLC, TELADOC HEALTH INTERNATIONAL SOCIEDAD ANÓNIMA, TelaDietitian, Teladoc Health Canada Inc., Teladoc Health Massachusetts Holdings Inc., Teladoc Health UK Ltd., and Yi Yi Medical Health Management Consulting (Shanghai) Co. Ltd..

Teladoc Health was founded in 2002.

The official website for Teladoc Health is www.teladochealth.com.

Teladoc Health is headquartered at 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577.

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at (203) 635-2002 or via email at [email protected]